The Beauty Health Company (SKIN)
NASDAQ: SKIN · Real-Time Price · USD
1.970
+0.030 (1.55%)
At close: Sep 26, 2025, 4:00 PM EDT
2.080
+0.110 (5.58%)
After-hours: Sep 26, 2025, 7:55 PM EDT
The Beauty Health Company Stock Forecast
Stock Price Forecast
The 3 analysts that cover The Beauty Health Company stock have a consensus rating of "Buy" and an average price target of $2.42, which forecasts a 22.84% increase in the stock price over the next year. The lowest target is $1.25 and the highest is $3.50.
Price Target: $2.42 (+22.84%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for The Beauty Health Company stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Hold Maintains $2 → $2.5 | Hold | Maintains | $2 → $2.5 | +26.90% | Sep 22, 2025 |
| Roth Capital | Roth Capital | Strong Buy Initiates $3.5 | Strong Buy | Initiates | $3.5 | +77.66% | Sep 19, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $1.5 → $1.25 | Hold | Maintains | $1.5 → $1.25 | -36.55% | May 5, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $1.75 → $1.5 | Hold | Maintains | $1.75 → $1.5 | -23.86% | Mar 13, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $1.25 → $1.75 | Hold | Maintains | $1.25 → $1.75 | -11.17% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
299.64M
from 334.29M
Decreased by -10.37%
Revenue Next Year
317.24M
from 299.64M
Increased by 5.87%
EPS This Year
-0.12
from -0.36
EPS Next Year
-0.10
from -0.12
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 314.3M | 349.2M | ||
| Avg | 299.6M | 317.2M | ||
| Low | 284.2M | 296.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -6.0% | 16.5% | ||
| Avg | -10.4% | 5.9% | ||
| Low | -15.0% | -1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.09 | -0.01 | ||
| Avg | -0.12 | -0.10 | ||
| Low | -0.15 | -0.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.